Cytokine Storm Induced by SARS-CoV-2 and the Drug Therapy
ZHANG Jing-wen1,2, HU Xin2, JIN Peng-fei2*
1. Department of Pharmacy Administration and Clinical Pharmacy,School of Pharmaceutical Science, Peking University, Beijing 100191, China; 2. Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Drug Clinical Risk and Personalized Medication Evaluation, Beijing 100730, China
Abstract：Novel coronavirus 2019 (SARS-CoV-2) infection outbreak has occurred in Wuhan since December 2019.Cytokine storm (inflammatory factor storm)was suggested to be involved in the sudden deterioration of some SARS-CoV-2 infectors in the recent reports.However, no medicine was specific to the treatment of cytokine storm so far. This paper summarized the mechanism and potential therapeutic drugs of cytokine storm based on literature review and analysis, so as to provide references for the treatment of SARS-CoV-2.
张竞文, 胡欣, 金鹏飞. 新型冠状病毒引起的细胞因子风暴及其药物治疗[J]. 中国药学杂志, 2020, 55(5): 333-336.
ZHANG Jing-wen, HU Xin, JIN Peng-fei. Cytokine Storm Induced by SARS-CoV-2 and the Drug Therapy. Chinese Pharmaceutical Journal, 2020, 55(5): 333-336.
HUANG K J, SU I J, THERON M, et al. An interferon-γ-related cytokine storm in SARS patients[J]. J Med Virol, 2005, 75(2): 185-194.
[2]
HUANG C, WANG Y, WANG X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [J]. Lancet, 2020,DOI: 10.1016/S0140-6736(20)30183-5.
[3]
JENNIFER R T, MARCUS J K,CAMERON P S, et al. Into the eye of the cytokine storm [J]. Microbiol Mol Biol Rev, 2012, 76(1):16-32.
[4]
ZHANG H Y,XIE X,ZHANG K J, et al. Effects of cytokine storm on influenza virus infection and its prevention and treatment [J]. Chin J Cell Mol Imm(细胞与分子免疫学杂志),2013,29(5):556-559.
[5]
ZHANG Y L,JIANG C Y.Cytokine storms: the dominant hand in acute respiratory distress syndrome [J]. Life Sci(生命科学),2015,27(5):554-557.
[6]
CHATENOUD L, FERRAN C, REUTER A, et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma[J]. N Engl J Med, 1989, 320 (21) :1420-1421.
[7]
ERRARA J L, ABHYANKAR S, GILLILAND D G.Cytokine storm of graft-versus-host disease:a critical effector role for interleukin-1[J]. Transplant Proc, 1993, 25 (1 Pt 2) :1216-1217.
[8]
DE JONG M D, SIMMONS C P, THANH T T, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia[J]. Nat Med, 2006, 12 (10) :1203-1207.
[9]
WANG J F, JIN B, CAO F L. Advances in the study of cytokine release syndrome induced by CAR-T cell therapy[J]. J Chin Pract Diag Ther(中华实用诊断与治疗杂志),2018,32(12):1228-1231.
[10]
SHIMABUKURO-VORNHAGEN A, GÖDEL P, SUBLKLEWE M, et al. Cytokine release syndrome [J]. J Immunother Cancer, 2018, 6(1):56.
[11]
SHINYA K, GAO Y, CILLONIZ C, et al. Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virus-induced viral pneumonia in the rhesus macaque[J]. J Virol, 2012, 86(11):6055-6066.
[12]
WANG Q, ZHANG T, SU F,et al. Research status of adverse reactions of cytokine release syndrome[J]. Chin J Clin Pharmacol(中国临床药理学杂志), 2018, 34 (7):906-909.
[13]
MAUDE S L, BARRETT D, TEACHEY D T, et al.Managing cytokine release syndrome associated with novel T cell-engaging therapies[J]. Cancer, 2014, 20 (2):119-122.
[14]
TANAKA T. IL-6 blockade therapy for inflammatory diseases: current perspectives and future directions [J]. Nihon Rinsho Meneki Gakkai Kaishi, 2015, 38 (6): 433-442.
[15]
ALVI R M, FRIGAULT M J, FRADLEY M G, et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T) [J]. J Am Coll Cardiol, 2019, 74 (25): 3099-3108.
[16]
GRUPP S A, MAUDE S, APLENC R, et al. T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce complete responses and long-term persistence without GVHD in children with relapsed, refractory ALL [J]. Cancer Res, 2014, 74 (20s): PR06.
[17]
SUN Y,ZHANG B,CHEN H.Mechanism and clinical treatment of cytokine release syndrome after CAR-T treatment [J]. Chin J Cancer Biother(中国肿瘤生物治疗杂志),2019,26(4):365-373.
[18]
RUSSEL C D,MILLAR J E,BAILLIEJ K. Clinical evidence does not support corticosteroid treatment for SARS-CoV-2 lung injury[J].Lancet,2020,DOI:10.1016/S0140-6736(20)30317-2.
[19]
ZOU Y, FAN L, XU W, et al. Progress of cytokine release syndrome caused by chimeric antigen receptor t-cell immunotherapy [J]. J Leuk Lymph, 2017, 26 (11): 697-701.
[20]
NORELLI M, CAMISA B, BARBIERA G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells[J]. Nat Med, 2018, 24 (6):739-748.
[21]
GIAVRIDIS T, VANDERSTEGEN S J C, EYQUEM J, et al. CAR-T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade[J]. Nat Med, 2018, 24 (6) :731-738.
[22]
STAEDTKE V, BAI R Y, KIM K, et al. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome[J]. Nature, 2018, 564 (7735):273-277.
[23]
TAO G F, ZHANG S S, ZHU L Y, et al. Pharmacological mechanism and clinical application of ulinastatin [J]. J China Pharm(中国药房),2017,28(35):5020-5023.
[24]
FU Q. Comparison of the anti-inflammatory effects of ulinastatin and glucocorticoid on septic rats [D]. Shijiazhuang:Hebei Medical University,2012.
[25]
YIN S J. Chinese biology: plasma products from recovered patients were put into clinical practice, and signs and symptoms of the patients improved significantly [EB/OL]. [2020-02-14] http://www.xinhuanet. com/2020-02/14/c_1125573091. htm.
2020, Vol. 55 
